Balsm Alofoq Medical Co. (9620.SR) — Income statement
Revenue, gross profit, operating income, net income, and EPS for Balsm Alofoq Medical Co. — annual and quarterly.
| Metric (SAR Millions) | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Revenue & Gross Profit | |||||
| Revenue | 20↑2.6% | 20↑10.1% | 18↑6.0% | 17 | |
| Cost of Revenue | 13↑20.2% | 10↑6.2% | 10↑11.6% | 9 | |
| Gross Profit | 8↓17.0% | 9↑17.5% | 8↓2.1% | 8 | |
| Operating Expenses | |||||
| R&D Expenses | 0.00 | 0.00 | 0.00 | 0.00 | |
| General & Administrative Expenses | 0.00↓100.0% | 3↑14.1% | 3↓23.1% | 4 | |
| Selling & Marketing Expenses | 0.00↓100.0% | 2↑11.8% | 1↑32.3% | 1 | |
| SG&A Expenses | 0.00↓100.0% | 5↑20.4% | 4↓17.6% | 5 | |
| Other Expenses | 5 | 0.00 | 0.00↑100.0% | -0.02 | |
| Operating Expenses | 5↑12.5% | 5↑20.4% | 4↓17.2% | 5 | |
| Total Costs & Expenses | 18↑17.8% | 15↑208.7% | -14↓204.7% | 13 | |
| Operating Results | |||||
| Operating Income | 3↓45.8% | 5↑14.7% | 4↑10.8% | 4 | |
| Depreciation & Amortization | 0.00↓100.0% | 1↓4.0% | 1↓13.1% | 1 | |
| EBITDA | 3↓45.8% | 5↓16.0% | 6↑8.5% | 5 | |
| EBIT | 3↓45.8% | 5↑6.8% | 4↑16.4% | 4 | |
| Interest & Other Income | |||||
| Net Interest Income | 0.00↑100.0% | -0.16↑13.5% | -0.18↓0.4% | -0.18 | |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 0.00↓100.0% | 0.16↓13.5% | 0.18↑0.4% | 0.18 | |
| Non-Operating Income | 0.00↓100.0% | 0.05↑116.5% | -0.31↓263.9% | -0.08 | |
| Other Income / Expenses | -3↓943.0% | 0.30↑138.0% | 0.13↑235.8% | -0.09 | |
| Income Before Tax | 0.00↓100.0% | 5↑18.4% | 4↑17.2% | 4 | |
| Income Tax Expense | 0.00↓100.0% | 0.26↑173.1% | 0.10↓19.7% | 0.12 | |
| Net Income & EPS | |||||
| Net Income from Continuing Operations | 0.00↓100.0% | 5↑14.8% | 4↑18.5% | 4 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 2↓58.8% | 5↑14.8% | 4↑18.5% | 4 | |
| Bottom-Line Net Income | 2↓58.8% | 5↑14.8% | 4↑18.5% | 4 | |
| EPS (Basic) | 0.79↓66.2% | 2.34↑40.5% | 1.67↑18.5% | 1.41 | |
| EPS (Diluted) | 0.79↓66.2% | 2.34↑40.5% | 1.67↑18.5% | 1.41 | |
| Weighted Average Shares | 2↑21.9% | 2↓18.3% | 3↑0.0% | 3 | |
| Weighted Average Diluted Shares | 2↑21.9% | 2↓18.3% | 3↑0.0% | 3 | |
* All figures in Millions of SAR, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.